Literature DB >> 30342911

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Satish Shanbhag1, Vinay Prasad2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30342911     DOI: 10.1016/j.ejca.2018.09.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.

Authors:  A J N Raymakers; S Costa; D Cameron; D A Regier
Journal:  BMC Cancer       Date:  2020-10-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.